FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553520932> ?p ?o ?g. }

• W2553520932 abstract "Abstract The introduction of Rituximab (R) in the treatment of B-NHL resulted in improvement in first line therapies for indolent (ind.) and aggressive (agg.) B-NHL. However, the value of R in intensive chemotherapy relapse strategies has not definitely been demonstrated. In a phase I/II clinical trial we have demonstrated safety of R as an in vivo purging agens in salvage and high dose therapy for relapsed/refractory B-NHL. This led, with promising response rates, to the initiation of a multicenter phase II trial to further prove therapeutic efficacy. Inclusion criteria were: Pt < 65 years, ECOG < 3, relapse or progression for patients with ind. NHL and induction failure or relapse for pts with agg. NHL. Salvage therapy consisted of 2 cycles of DexaBEAM in which R was included on day 1; stem cells were collected after cycle II. HDT, requiring at least stable disease to salvage therapy, consisted of BEAM (agg. NHL) or TBI/Cy (ind. NHL) with 2 additional doses of R. In 2000 the study was initiated at multiple centres and until now 77 patients have been enrolled. As of 06/04, data are available of 66 patients. Diagnosis in agg. entities include: Diffuse large cell lymphoma: 34pts; Follicle centre lymphoma (FCL) grade III: 3 patients or Mantle cell lymphoma: 5pts. Patients with ind. NHL had FCL grade I–II: 28pts or marginal zone lymphoma: 3pts. Median age was 53.5y (range 18–64y). For patients with agg. NHL (n=42) time from diagnosis to inclusion into the study was 1.3y, median number of pre-treatment was 1 and 18% of patients had received Rituximab in a prior treatment line, best response to last treatment was CR: 20, PR: 10 and inferior response in 7/37 pts. During salvage and mobilization therapy 13/39 (33%) patients were taken of study due to: progress: 8 pts., death not related to treatment: 1 and mobilization failure: 4 pts. Corresponding figures for ind. NHL were 2.5y from diagnosis to inclusion, median pre-treatment 1 with 20% pre-treatment with Rituximab. Reasons for inclusion were induction failure in 4, 1. rel. in 15 and >1. rel. in 3 pts. 4 pts did not complete treatment due to death (1 sepsis, 1 unrelated reason) or mobil. failure (2), respectively. HDT (n=18 agg. NHL, 19 ind. NHL) could be performed without uncommon toxicities, one septic death occurred. In the agg. NHL group response to treatment in evaluated patients was CR in 14/18, PR in 2 and PD in 2. Corresponding figures for ind. NHL are CR in 18/19 and PR in 1/19 pts. With a median follow up of 20 months for patients undergoing HDT PFS and OS rates are 63% and 79% for agg. NHL and 65% and 100% for ind. NHL, respectively. In respect to historical data and in lack of randomized trials to test for the efficacy of R in HDT concepts, the result of this multicenter phase II study underlines the efficacy of this combined modality treatment approach in patients with chemosensitive disease. This seems to be favourable to prior experiences and probably reflects the benefit of the addition of R. However, as 1/4 of patients with agg. NHL still fail to respond to salvage therapy, the combination of R with intensive chemotherapy can not overcome chemoresistance in all patients, therefore defining a patient subgroup, for which more efficient strategies have to be developed." @default.
• W2553520932 created "2016-11-30" @default.
• W2553520932 creator A5011863718 @default.
• W2553520932 creator A5018364683 @default.
• W2553520932 creator A5027618242 @default.
• W2553520932 creator A5027891989 @default.
• W2553520932 creator A5029904007 @default.
• W2553520932 creator A5029912133 @default.
• W2553520932 creator A5036175709 @default.
• W2553520932 creator A5047365928 @default.
• W2553520932 creator A5059745295 @default.
• W2553520932 creator A5060642289 @default.
• W2553520932 creator A5061020169 @default.
• W2553520932 creator A5061380659 @default.
• W2553520932 creator A5090947507 @default.
• W2553520932 date "2004-11-16" @default.
• W2553520932 modified "2023-10-18" @default.
• W2553520932 title "Efficacy of Rituximab Combined in Salvage- and High Dose-Therapy (HDT) for Patients with Relapsed NHL; Interim Analysis of a Multicenter Phase II Study." @default.
• W2553520932 doi "https://doi.org/10.1182/blood.v104.11.1325.1325" @default.
• W2553520932 hasPublicationYear "2004" @default.
• W2553520932 type Work @default.
• W2553520932 sameAs 2553520932 @default.
• W2553520932 citedByCount "0" @default.
• W2553520932 crossrefType "journal-article" @default.
• W2553520932 hasAuthorship W2553520932A5011863718 @default.
• W2553520932 hasAuthorship W2553520932A5018364683 @default.
• W2553520932 hasAuthorship W2553520932A5027618242 @default.
• W2553520932 hasAuthorship W2553520932A5027891989 @default.
• W2553520932 hasAuthorship W2553520932A5029904007 @default.
• W2553520932 hasAuthorship W2553520932A5029912133 @default.
• W2553520932 hasAuthorship W2553520932A5036175709 @default.
• W2553520932 hasAuthorship W2553520932A5047365928 @default.
• W2553520932 hasAuthorship W2553520932A5059745295 @default.
• W2553520932 hasAuthorship W2553520932A5060642289 @default.
• W2553520932 hasAuthorship W2553520932A5061020169 @default.
• W2553520932 hasAuthorship W2553520932A5061380659 @default.
• W2553520932 hasAuthorship W2553520932A5090947507 @default.
• W2553520932 hasConcept C121332964 @default.
• W2553520932 hasConcept C126322002 @default.
• W2553520932 hasConcept C141071460 @default.
• W2553520932 hasConcept C142424586 @default.
• W2553520932 hasConcept C143998085 @default.
• W2553520932 hasConcept C168563851 @default.
• W2553520932 hasConcept C2775965419 @default.
• W2553520932 hasConcept C2776694085 @default.
• W2553520932 hasConcept C2778822529 @default.
• W2553520932 hasConcept C2779338263 @default.
• W2553520932 hasConcept C2780653079 @default.
• W2553520932 hasConcept C2780775027 @default.
• W2553520932 hasConcept C2992435398 @default.
• W2553520932 hasConcept C31760486 @default.
• W2553520932 hasConcept C535046627 @default.
• W2553520932 hasConcept C61943457 @default.
• W2553520932 hasConcept C71924100 @default.
• W2553520932 hasConcept C87355193 @default.
• W2553520932 hasConcept C90924648 @default.
• W2553520932 hasConceptScore W2553520932C121332964 @default.
• W2553520932 hasConceptScore W2553520932C126322002 @default.
• W2553520932 hasConceptScore W2553520932C141071460 @default.
• W2553520932 hasConceptScore W2553520932C142424586 @default.
• W2553520932 hasConceptScore W2553520932C143998085 @default.
• W2553520932 hasConceptScore W2553520932C168563851 @default.
• W2553520932 hasConceptScore W2553520932C2775965419 @default.
• W2553520932 hasConceptScore W2553520932C2776694085 @default.
• W2553520932 hasConceptScore W2553520932C2778822529 @default.
• W2553520932 hasConceptScore W2553520932C2779338263 @default.
• W2553520932 hasConceptScore W2553520932C2780653079 @default.
• W2553520932 hasConceptScore W2553520932C2780775027 @default.
• W2553520932 hasConceptScore W2553520932C2992435398 @default.
• W2553520932 hasConceptScore W2553520932C31760486 @default.
• W2553520932 hasConceptScore W2553520932C535046627 @default.
• W2553520932 hasConceptScore W2553520932C61943457 @default.
• W2553520932 hasConceptScore W2553520932C71924100 @default.
• W2553520932 hasConceptScore W2553520932C87355193 @default.
• W2553520932 hasConceptScore W2553520932C90924648 @default.
• W2553520932 hasLocation W25535209321 @default.
• W2553520932 hasOpenAccess W2553520932 @default.
• W2553520932 hasPrimaryLocation W25535209321 @default.
• W2553520932 hasRelatedWork W1999048711 @default.
• W2553520932 hasRelatedWork W2085413477 @default.
• W2553520932 hasRelatedWork W2126772526 @default.
• W2553520932 hasRelatedWork W2199158384 @default.
• W2553520932 hasRelatedWork W2561950317 @default.
• W2553520932 hasRelatedWork W2907016405 @default.
• W2553520932 hasRelatedWork W3040245446 @default.
• W2553520932 hasRelatedWork W3096042667 @default.
• W2553520932 hasRelatedWork W3096353690 @default.
• W2553520932 hasRelatedWork W91236835 @default.
• W2553520932 isParatext "false" @default.
• W2553520932 isRetracted "false" @default.
• W2553520932 magId "2553520932" @default.
• W2553520932 workType "article" @default.